Replies to post #69953 on CV Sciences Inc (CVSI)

[Wolf-man jack]

Pet Smart and Petco already have CBD line of products with different vendors. Most pet owners will be purchasing from these two brick and mortar. The pet line will not make or break CVSI in the short run you understand. It makes better sense to use capital for other product lines that will and do make better choices. Relax young lad. Have mercy wolf ahoo

[Wolf-man jack]

You predict $650,000. You might want to add another 0 to the equation you understand. Have Mercy Wolf AHOOOOOOO

Zacks Consensus Estimate

This company is expected to post quarterly loss of $0.02 per share in its upcoming report, which represents no change from the year-ago quarter.

Revenues are expected to be $6.32 million, down 49.8% from the year-ago quarter.

[Smooth_Legend]

FULL LINE OF SOOTHING HEMP EXTRACTS FORMULATED EXCLUSIVELY FOR DOGS AND CATS

SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced the launch of PlusCBD™ Pet, a full line of hemp extracts formulated exclusively for dogs and cats.

Made with the same trusted hemp extracts used in CV Sciences’ best-selling CBD products, PlusCBD™ Pet is available in 250mg and 500mg formats with pet friendly flavors, including beef, chicken, peanut butter and salmon, as well as unflavored. PlusCBD™ Pet will be sold across the Company’s natural and online retail channels, with plans to expand into the pet specialty channel and food, drug and mass retail channel.

The U.S. Pet CBD market grew to over 10 times its 2018 size in 2019, producing $321 million in sales, and is projected to reach $563 million by the end of 2020, according to Brightfield Group. Growth is being driven by pet owners looking for natural alternatives for pets’ medical ailments, including anxiety, pain, or other serious conditions that have not responded well to other treatments, and is expected to make up a $1.7 billion market by the end of 2025, based on Brightfield Group data.

“PlusCBD™ Pet provides us with an exciting opportunity to leverage our brand equity and retail distribution channels to participate in the growing pet CBD market,” said Joseph Dowling, Chief Executive Officer, CV Sciences. “We believe the pet CBD category will continue to grow as more research demonstrates the health benefits of CBD for dogs and cats. Our employees have supplemented their pets with our human PlusCBD™ products for years, now we are pleased to have an opportunity to help all pet parents love their pets with our soothing PlusCBD™ Pet products formulated specifically for animals.”

https://www.thisishealthtransformed.com/PlusCBD-PET
https://ir.cvsciences.com/press-releases/detail/168/cv-sciences-inc-announces-launch-of-pluscbd-pet

[Wolf-man jack]

Wolf Says; Have Mercy

“Our employees have supplemented their pets with our human PlusCBD™ products for years, now we are pleased to have an opportunity to help all pet parents love their pets with our soothing PlusCBD™ Pet products formulated specifically for animals.”

Say What